1. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Issue 3 (March 2023) Authors: Brown, Janet E; Royle, Kara-Louise; Gregory, Walter; Ralph, Christy; Maraveyas, Anthony; Din, Omar; Eisen, Timothy; Nathan, Paul; Powles, Tom; Griffiths, Richard; Jones, Robert; Vasudev, Naveen; Wheater, Matthew; Hamid, Abdel; Waddell, Tom; McMenemin, Rhona; Patel, Poulam; Larkin, James; Faust, G... Journal: Lancet oncology Issue: Volume 24:Issue 3(2023) Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗